News
Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics
Mirroring results in patients with type 2 diabetes, semaglutide (Wegovy; Novo Nordisk) reduces cardiovascular events in patients with overweight or obesity and preexisting CVD who are not diabetic, according to full results of the SELECT trial.
Ania Jastreboff, MD, PhD (Yale School of Medicine, New Haven, CT), the discussant for Lincoff’s presentation, said it will be important to investigate the physiology to get to the bottom of the finding, which could be related to effects on inflammation, endothelial function, or other factors. But it’s likely, she said, that the gains are due to a combination of the indirect effects of weight loss—which include improvements in hypertension, hyperlipidemia, and glycemic control—and direct effects of the drug.
Source: tctMD